Proinsulin maturation disorder is a contributor to the defect of subsequent conversion to insulin in β-cells

Biochemical and Biophysical Research Communications

Volumn 411, Issue 1, 2011, Pages 150-155

  Wang, Jie ^a   Osei, Kwame ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Convertase post translational defects; Defective conversion; Hyperproinsulinemia; Islets; Proinsulin maturation disorder

Indexed keywords

INSULIN; PROINSULIN; PROPROTEIN CONVERTASE 1; PROPROTEIN CONVERTASE 2;

ANIMAL CELL; ARTICLE; DIABETES MELLITUS; DISORDERS OF AMINO ACID AND PROTEIN METABOLISM; HOMEOSTASIS; HORMONE METABOLISM; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN MATURATION DISORDER; PROTEIN PROCESSING;

ANIMALS; HYPERINSULINISM; INSULIN; INSULIN-SECRETING CELLS; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; PROINSULIN;

EID: 79960565850     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.06.119     Document Type: Article

References (29)

1. Steiner D.F., Steiner G.I., Bell A.H., Chan S.J. Chemistry and biosynthesis of the islet hormones: insulin, islet amyloid polypeptide (amylin), glucagon, somatostatin, and pancreatic polypeptide. Endocrinology 2001, 667-696. W.B. Saunders, New York. L.J. DeGroot, J.L. Jameson (Eds.).
2. Roder M.E., Knip M., Hartling S.G., et al. Disproportionately elevated proinsulin levels precede the onset of insulin-dependent diabetes mellitus in siblings with low first phase insulin responses. The Childhood Diabetes in Finland Study Group. J. Clin. Endocrinol. Metab. 1994, 79:1570-1575.
3. Snorgaard O., Hartling S.G., Binder C. Proinsulin and C-peptide at onset and during 12 months cyclosporin treatment of type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1990, 33:36-42.
4. Truyen I., De Pauw P., Jorgensen P.N., et al. Proinsulin levels and the proinsulin:c-peptide ratio complement autoantibody measurement for predicting type 1 diabetes. Diabetologia 2005, 48:2322-2329.
5. Yoshioka N., Kuzuya T., Matsuda A., Taniguchi M., Iwamoto Y. Serum proinsulin levels at fasting and after oral glucose load in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1988, 31:355-360.
6. Porte D., Kahn S.E. Hyperproinsulinemia and amyloid in NIDDM. Clues to etiology of islet beta-cell dysfunction?. Diabetes 1989, 38:1333-1336.
7. Temple R.C., Carrington C.A., Luzio S.D., et al. Insulin deficiency in non-insulin-dependent diabetes. Lancet 1989, 1:293-295.
8. Saad M.F., Kahn S.E., Nelson R.G., et al. Disproportionately elevated proinsulin in Pima Indians with noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 1990, 70:1247-1253.
9. Leahy J.L., Bonner-Weir S., Weir G.C. Beta-cell dysfunction induced by chronic hyperglycemia. Current ideas on mechanism of impaired glucose-induced insulin secretion. Diabetes Care 1992, 15:442-455.
10. Rhodes C.J., Alarcon C. What beta-cell defect could lead to hyperproinsulinemia in NIDDM? Some clues from recent advances made in understanding the proinsulin-processing mechanism. Diabetes 1994, 43:511-517.
11. Roder M.E., Kahn S.E. Suppression of beta-cell secretion by somatostatin does not fully reverse the disproportionate proinsulinemia of type 2 diabetes. Diabetes 2004, 53(Suppl. 3):S22-S25.
12. Fraze E., Donner C.C., Swislocki A.L., et al. Ambient plasma free fatty acid concentrations in noninsulin-dependent diabetes mellitus: evidence for insulin resistance. J. Clin. Endocrinol. Metab. 1985, 61:807-811.
13. Swislocki A.L., Chen Y.D., Golay A., Chang M.O., Reaven G.M. Insulin suppression of plasma-free fatty acid concentration in normal individuals and patients with type 2 (non-insulin-dependent) diabetes. Diabetologia 1987, 30:622-626.
14. Reaven G.M., Hollenbeck C., Jeng C.Y., Wu M.S., Chen Y.D. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24h in patients with NIDDM. Diabetes 1988, 37:1020-1024.
15. Furukawa H., Carroll R.J., Swift H.H., Steiner D.F. Long-term elevation of free fatty acids leads to delayed processing of proinsulin and prohormone convertases 2 and 3 in the pancreatic beta-cell line MIN6. Diabetes 1999, 48:1395-1401.
16. Roder M.E., Dinesen B., Hartling S.G., et al. Intact proinsulin and beta-cell function in lean and obese subjects with and without type 2 diabetes. Diabetes Care 1999, 22:609-614.
17. Dixit P.K., Lowe I., Lazarow A. Effect of alloxan on the insulin content of micro-dissected mammalian pancreatic islets. Nature 1962, 195:388-389.
18. Hellman B., Lernmark A. Evidence for an inhibitor of insulin release in the pancreatic islets. Diabetologia 1969, 5:22-24.
19. Permutt M.A., Kipnis D.M. Insulin biosynthesis: studies of islet polyribosomes (nascent peptides-sucrose gradient analysis-gel filtration). Proc. Natl. Acad. Sci. USA 1972, 69:505-509.
20. Rapoport T.A., Prehn S., Tsamaloukas A., et al. Biosynthesis of proinsulin of carp (Cyprinus carpio) and characterization and cloning of mRNA. Ann. N. Y. Acad. Sci. 1980, 343:111-132.
21. Wang J., Chen Y., Yuan Q., Tang W., Zhang X., Osei K. Control of precursor maturation and disposal is an early regulative mechanism in the normal insulin production of pancreatic beta-cells. PLoS One 2011, 6:e19446.
22. Nozaki J., Kubota H., Yoshida H., et al. The endoplasmic reticulum stress response is stimulated through the continuous activation of transcription factors ATF6 and XBP1 in Ins2+/Akita pancreatic beta cells. Genes Cells 2004, 9:261-270.
23. Wang J., Takeuchi T., Tanaka S., et al. A mutation in the insulin 2 gene induces diabetes with severe pancreatic beta-cell dysfunction in the Mody mouse. J. Clin. Invest. 1999, 103:27-37.
24. Wang J., Cao Y., Chen Y., Gardner P., Steiner D.F. Pancreatic beta cells lack a low glucose and O2-inducible mitochondrial protein that augments cell survival. Proc. Natl. Acad. Sci. USA 2006, 103:10636-10641.
25. Laedtke T., Kjems L., Porksen N., et al. Overnight inhibition of insulin secretion restores pulsatility and proinsulin/insulin ratio in type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 2000, 279:E520-E528.
26. Rachman J., Levy J.C., Barrow B.A., Manley S.E., Turner R.C. Relative hyperproinsulinemia of NIDDM persists despite the reduction of hyperglycemia with insulin or sulfonylurea therapy. Diabetes 1997, 46:1557-1562.
27. Chan S.J., Seino S., Gruppuso P.A., Schwartz R., Steiner D.F. A mutation in the B chain coding region is associated with impaired proinsulin conversion in a family with hyperproinsulinemia. Proc. Natl. Acad. Sci. USA 1987, 84:2194-2197.
28. Stoy J., Edghill E.L., Flanagan S.E., et al. Insulin gene mutations as a cause of permanent neonatal diabetes. Proc. Natl. Acad. Sci. USA 2007, 104:15040-15044.
29. Edghill E.L., Flanagan S.E., Patch A.M., et al. Insulin mutation screening in 1044 patients with diabetes: mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood. Diabetes 2008, 57:1034-1042.